ADA Congress 2015 in Boston (USA) - an overview of the main topics

From July 5 to July 9, 2015 in Convention Center in Boston (USA) there took place anniversary 75th session of the annual congress of the American Diabetic Association (ADA). The congress united more than 14000 participants from 124 countries. Programs of scientific sessions of the congress included the most topical issues of diabetology: modern approaches to diagnostics, prevention and treatment of DM and its complications, the results of the international researches of anti-diabetic preparations, problems connected with diabetes 2 types and obesity and many others

Sovremennye aspekty patogenezasakharnogo diabeta 1 tipa

ГУ Эндокринологический научный центр РАМН, Москв

Prospects of antigen-specific therapy in type 1 diabetes mellitus

Type 1 diabetes mellitus is commonly recognized as an autoimmune disease characterized by progressive destruction of pancreatic ?-beta-cells. Progress in diagnostics at preclinical stage is accompanied with active development of preventive measures. So far, there are no specific therapeutic agents approved for clinical practice. However, ongoing large-scale studies have outlined some promising solutions, antigen-specific immunotherapy being one of them

Diagnostic and prognostic value of autoantibodies for diabetes mellitus. A novel T1D autoimmunity target - zinc transporter 8 (ZnT8)

The progressive loss of beta cells in Type 1 Diabetes (T1D) is a result of chronic autoimmune attack targeted at diverse molecules expressing in thepancreatic beta cells. The appearance of cellular and humoral autoimmunity precedes the clinical manifestation of T1D. There are several autoantigenswhich are supposed to be involved in pathogenesis of TD1. Zinc transporter 8 (ZnT8; Slc30A8) was identified as a novel T1D autoimmunitytarget

Ketosis-prone type 2 diabetes mellitus (review of the literature)

Idiopathic ketosis-prone type 2 diabetes is intermediate between two major forms of diabetes mellitus. The aim of this review is to analyse factors contributingto its development and occurrence and to discuss approaches to differential diagnosis of this pathology

Vozmozhnosti kletochnykh tekhnologiy v lechenii sakharnogo diabeta

8?11 сентября 2008 года состоялась очередная 44 сессия конгресса Европейской ассоциации по изучению сахарного диабета (EASD). Программы научных сессий включали наиболее актуальные вопросы этиопатогенеза и лечения сахарного диабета (СД) и его осложнений, а также освещали современные подходы его диагностики и профилактики

The role of apoptosis in pathogenesis of type 1 diabetes mellitus

Type 1 diabetes mellitus (DM1) is known to be associated with progressive destruction of pancreatic beta-cells. Apoptosis plays the key role in this destructiveprocess. The paper focuses on major mechanisms underlying activation of beta-cell apoptosis and its role in regulation of immune processes inpatients with DM1

Functional activity and peripheral insulin resistance in patients with different types of onset of diabetes mellitus

Aim. To evaluate changes in functional activity and insulin resistance (IR) in patients with different types of onset of diabetes mellitus(DM). Materials and methods. We examined 166 subjects which were subdivided into 4 study groups and 1 control group. Assessment of totalbeta-cell functional activity and degree of IR (according to HOMA-model) was conducted in patients with different variants of DM onsetand in the group of high risk for type 1 DM. Results. The most significant decrease in beta-cell functional activity was found in patients with type 1 diabetes mellitus (HOMA-F 8.9%).Onset of LADA (Latent autoimmune diabetes in adults) and type 2 diabetes mellitus (T2DM) was also characterized by decreasein beta-cell functional activity (HOMA-F 39.2% and 63.9%, respectively), as well as by development of IR: HOMA-IR 3.7 and 7.2,respectively. Conclusion. Clinical onset of LADA and T2DM occurs against the background of decreased beta-cell functional activity and compromisedperipheral insulin sensitivity

Autoimmunnyy poliglandulyarnyy sindrom III tipa (DTZ, sakharnyy diabet I tipa, autoimmunnyy glomerulonefrit)

Аутоиммунные полигландулярные синдромы (АПС) ? первичное аутоиммунное поражение двух и более периферических эндокринных желез, приводящее, как правило, к их недостаточности, часто сочетающееся с различными органоспецифическими заболеваниями аутоиммунного генеза. Представляем случай множественной аутоиммунной патологии с поражением эндокринных желез и неэндокринных органов: сочетание СД 1 типа, диффузного токсического зоба (ДТЗ) и хронического гломерулонефрита (ХГ), который может быть расценен как аутоиммунный полигландулярный синдром 3 типа